

FORM PTO-1390 (Modified)
(REV. 11-2000)

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

ATTORNEY'S DOCKET NUMBER

**TRANSMITTAL LETTER TO THE UNITED STATES
DESIGNATED/ELECTED OFFICE (DO/EO/US)
CONCERNING A FILING UNDER 35 U.S.C. 371**

SERVIER 427 PCT

U.S. APPLICATION NO. (IF KNOWN, SEE 37 CFR

10/502479INTERNATIONAL APPLICATION NO.
FR03 00200INTERNATIONAL FILING DATE
January 22, 2003PRIORITY DATE CLAIMED
January 23, 2002

TITLE OF INVENTION

ORODISPERSIBLE PHARMACEUTICAL COMPOSITION OF PERINDOPRIL.

APPLICANT(S) FOR DO/EO/US

Patrick WUTHRICH, Herve ROLLAND, Marc JULIEN

Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:

1. ☒ This is a **FIRST** submission of items concerning a filing under 35 U.S.C. 371.
2. ☐ This is a **SECOND** or **SUBSEQUENT** submission of items concerning a filing under 35 U.S.C. 371.
3. ☒ This is an express request to begin national examination procedures (35 U.S.C. 371(f)). The submission must include items (5), (6), (9) and (24) indicated below.
4. ☐ The US has been elected by the expiration of 19 months from the priority date (Article 31).
5. ☒ A copy of the International Application as filed (35 U.S.C. 371 (c) (2))
 - a. ☐ is attached hereto (required only if not communicated by the International Bureau).
 - b. ☒ has been communicated by the International Bureau.
 - c. ☐ is not required, as the application was filed in the United States Receiving Office (RO/US).
6. ☒ An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)).
 - a. ☒ is attached hereto.
 - b. ☐ has been previously submitted under 35 U.S.C. 154(d)(4).
7. ☒ Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371 (c)(3))
 - a. ☐ are attached hereto (required only if not communicated by the International Bureau).
 - b. ☐ have been communicated by the International Bureau.
 - c. ☐ have not been made; however, the time limit for making such amendments has NOT expired.
 - d. ☒ have not been made and will not be made.
8. ☐ An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).
9. ☒ An oath or declaration of the inventor(s) (35 U.S.C. 371 (c)(4)).
10. ☐ An English language translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371 (c)(5)).
11. ☒ A copy of the International Preliminary Examination Report (PCT/IPEA/409).
12. ☒ A copy of the International Search Report (PCT/ISA/210).

Items 13 to 20 below concern document(s) or information included:

13. ☐ An Information Disclosure Statement under 37 CFR 1.97 and 1.98.
14. ☐ An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.
15. ☒ A **FIRST** preliminary amendment.
16. ☐ A **SECOND** or **SUBSEQUENT** preliminary amendment.
17. ☐ A substitute specification.
18. ☐ A change of power of attorney and/or address letter.
19. ☐ A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 35 U.S.C. 1.821 - 1.825.
20. ☐ A second copy of the published international application under 35 U.S.C. 154(d)(4).
21. ☐ A second copy of the English language translation of the international application under 35 U.S.C. 154(d)(4).
22. ☒ Express Mail Label No. **EV 509688489 US**
23. ☒ Other items or information:

PTO 1449**Claim to foreign priority benefits under 35USC § 119****Certified Copy of French Priority 02 00671 and Certified Translation thereof**

U.S. APPLICATION NO. (IF KNOWN, SEE 37 CFR <div style="font-size: 24pt; font-weight: bold; text-align: center;">10/502479</div>		INTERNATIONAL APPLICATION NO. <div style="font-weight: bold; text-align: center;">FR03 00200</div>		ATTORNEY'S DOCKET NUMBER <div style="font-weight: bold; text-align: center;">SERVIER 427 PCT</div>	
24. The following fees are submitted:. BASIC NATIONAL FEE (37 CFR 1.492 (a) (1) - (5)) : <div style="display: flex; justify-content: space-between;"> <div> <input type="checkbox"/> Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO and International Search Report not prepared by the EPO or JPO <input checked="" type="checkbox"/> International preliminary examination fee (37 CFR 1.482) not paid to USPTO but International Search Report prepared by the EPO or JPO <input type="checkbox"/> International preliminary examination fee (37 CFR 1.482) not paid to USPTO but international search fee (37 CFR 1.445(a)(2)) paid to USPTO <input type="checkbox"/> International preliminary examination fee (37 CFR 1.482) paid to USPTO but all claims did not satisfy provisions of PCT Article 33(1)-(4) <input type="checkbox"/> International preliminary examination fee (37 CFR 1.482) paid to USPTO and all claims satisfied provisions of PCT Article 33(1)-(4) </div> <div style="text-align: right;"> \$1080.00 \$920.00 \$770.00 \$730.00 \$100.00 </div> </div> <div style="text-align: right; font-weight: bold; margin-top: 5px;"> ENTER APPROPRIATE BASIC FEE AMOUNT = </div>				CALCULATIONS PTO USE ONLY <div style="border: 1px solid black; height: 100px; width: 100%;"></div>	
Surcharge of \$130.00 for furnishing the oath or declaration later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492 (e)).				<div style="border: 1px solid black; padding: 2px;">\$920.00</div> <div style="border: 1px solid black; padding: 2px;">\$0.00</div>	
CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE		
Total claims	13 - 20 =	0	x \$18.00	\$0.00	
Independent claims	1 - 3 =	0	x \$86.00	\$0.00	
Multiple Dependent Claims (check if applicable).				\$0.00	
TOTAL OF ABOVE CALCULATIONS =				\$920.00	
<input type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27. The fees indicated above are reduced by 1/2.				\$0.00	
SUBTOTAL =				\$920.00	
Processing fee of \$130.00 for furnishing the English translation later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492 (f)).				\$0.00	
TOTAL NATIONAL FEE =				\$920.00	
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31) (check if applicable).				\$0.00	
TOTAL FEES ENCLOSED =				\$920.00	
				Amount to be: refunded	\$
				charged	\$
<div style="display: flex; justify-content: space-between;"> <div style="width: 60%;"> <p>a. <input checked="" type="checkbox"/> A check in the amount of <u>\$920.00</u> to cover the above fees is enclosed.</p> <p>b. <input type="checkbox"/> Please charge my Deposit Account No. _____ in the amount of _____ to cover the above fees.</p> <p>c. <input checked="" type="checkbox"/> The Director is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. <u>08-3220</u></p> <p>d. <input type="checkbox"/> Fees are to be charged to a credit card. WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.</p> </div> <div style="width: 35%; text-align: center;"> <div style="font-size: 24pt; font-weight: bold; margin-bottom: 5px;">G. PATRICK SAGE</div> <div style="border-bottom: 1px solid black; width: 100%;"></div> <div style="font-weight: bold; margin-bottom: 5px;">G. PATRICK SAGE</div> <div style="border-bottom: 1px solid black; width: 100%;"></div> <div style="font-weight: bold; margin-bottom: 5px;">37,710</div> <div style="border-bottom: 1px solid black; width: 100%;"></div> <div style="font-weight: bold; margin-bottom: 5px;">23 July 2004</div> <div style="border-bottom: 1px solid black; width: 100%;"></div> </div> </div>					
NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.					
SEND ALL CORRESPONDENCE TO:					
<div style="display: flex; justify-content: space-between;"> <div style="width: 45%;"> <p>THE FIRM OF HUESCHEN AND SAGE 500 COLUMBIA PLAZA 350 EAST MICHIGAN AVENUE KALAMAZOO, MI 49007</p> <p>CUSTOMER NUMBER: 25,666</p> </div> <div style="width: 50%; text-align: center;"> <div style="font-size: 24pt; font-weight: bold; margin-bottom: 5px;">G. PATRICK SAGE</div> <div style="border-bottom: 1px solid black; width: 100%;"></div> <div style="font-weight: bold; margin-bottom: 5px;">G. PATRICK SAGE</div> <div style="border-bottom: 1px solid black; width: 100%;"></div> <div style="font-weight: bold; margin-bottom: 5px;">37,710</div> <div style="border-bottom: 1px solid black; width: 100%;"></div> <div style="font-weight: bold; margin-bottom: 5px;">23 July 2004</div> <div style="border-bottom: 1px solid black; width: 100%;"></div> </div> </div>					

CERTIFICATE OF MAILING BY "EXPRESS MAIL" (37 CFR 1.10)

Applicant(s): Patrick WUTHRICH, et al.

Docket No.

SERVIER 427 PCT

Application No.

Filing Date

Examiner

Customer No.

Group Art Unit


Invention: **ORODISPERSIBLE PHARMACEUTICAL COMPOSITION OF PERINDOPRIL.**

I hereby certify that the following correspondence:

New Application (16 pages), Transmittal Letter, Declaration and Power of Attorney, Listing of claims, IPER, ISR, PTO 1449, Certified copy of French Priority & Cetified translation thereof, and Check #72784 for \$920.00

(Identify type of correspondence)

is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on

July 23, 2004*(Date)*Linda Wooden*(Typed or Printed Name of Person Mailing Correspondence)**(Signature of Person Mailing Correspondence)*EV 509688489 US*("Express Mail" Mailing Label Number)***Note: Each paper must have its own certificate of mailing.**